Understanding the structure of the Vaccinia virus to improve antiviral treatments
Molecular architecture of the Vaccinia virion by structural proteomics
This study is looking at the structure of the Vaccinia virus to understand how it infects cells and how we can create better treatments and vaccines, which is important for keeping everyone safe from smallpox and similar viruses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-10465049 on NIH RePORTER |
What this research studies
This research investigates the molecular structure of the Vaccinia virus, a member of the poxvirus family, which has significant medical and agricultural implications. The study aims to uncover the complex architecture of the virus, particularly its envelope and capsid proteins, which play crucial roles in how the virus infects cells and responds to antiviral therapies. By using advanced structural proteomics techniques, the research seeks to provide insights that could lead to the development of new antiviral drugs and vaccines. This work is particularly relevant given the potential re-emergence of smallpox and related viruses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of poxvirus infections, including those in regions where outbreaks may occur.
Not a fit: Patients who are not at risk of poxvirus infections or those with existing immunity to these viruses may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antiviral treatments and vaccines against poxviruses.
How similar studies have performed: Previous research has shown success in understanding the structures of other viruses, which has led to advancements in antiviral therapies, suggesting potential for this approach.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Gershon, Paul D — University of California-Irvine
- Study coordinator: Gershon, Paul D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.